OncoMed Pharmaceuticals Inc
OncoMed Pharmaceuticals Inc (OMED): 5 pipeline candidates · ~11 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
11.2 months
D/E 0.35 · 0% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for OncoMed Pharmaceuticals Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$9.7M
Quarterly Burn
$15.2M
Runway
11.2 mo
Revenue
$10.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| etigilimab | Phase 1 |
| ipafricept | Phase 1 |
| navicixizumab | Phase 2 |
| tarextumab | Phase 2 |
| vantictumab | Phase 1 |
Frequently asked questions
How many drug candidates are in OncoMed Pharmaceuticals Inc's pipeline?
OncoMed Pharmaceuticals Inc (OMED) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is OncoMed Pharmaceuticals Inc's lead drug candidate?
OncoMed Pharmaceuticals Inc's most advanced tracked candidate is etigilimab (Phase 1) for Advanced or metastatic solid tumors.
What is OncoMed Pharmaceuticals Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, OncoMed Pharmaceuticals Inc has approximately 11.2 months of cash runway.
Who is the CEO of OncoMed Pharmaceuticals Inc?
Redwood City is the chief executive officer of OncoMed Pharmaceuticals Inc (OMED).
Get the full picture on OncoMed Pharmaceuticals Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.